| Date Filed | Type | Description |
| 10/04/2023 |
4
| Schoen Eric (CFO) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 150,000 options to buy
@ $17.54, valued at
$2.6M
|
|
| 10/04/2023 |
4
| Cook Robert Christopher (SVP & General Counsel) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 50,000 options to buy
@ $17.54, valued at
$877k
|
|
| 10/04/2023 |
4
| Kupiec James William (Chief Medical Officer) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 150,000 options to buy
@ $17.54, valued at
$2.6M
|
|
| 10/04/2023 |
4
| BARBIER REMI (President & CEO) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 300,000 options to buy
@ $17.54, valued at
$5.3M
Granted 150,000 options to buy
@ $17.54, valued at
$2.6M
|
|
| 08/24/2023 |
4
| ROBERTSON SANFORD (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Bought 30,000 shares
@ $17.45, valued at
$523.5k
|
|
| 08/23/2023 |
4
| Barry Richard (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Bought 1,906 shares
@ $16.8, valued at
$32k
Bought 16,571 shares
@ $16.65, valued at
$275.9k
|
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
4
| SCANNON PATRICK J MD PHD (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Exercised 1,000 options to buy
@ $0.95, valued at
$950 |
|
| 05/25/2023 |
4
| BARBIER REMI (President and CEO) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Paid exercise price by delivering 9,545 shares
@ $25.25, valued at
$241k
Paid exercise price by delivering 47,723 shares
@ $25.25, valued at
$1.2M
Exercised 14,285 options to buy
@ $16.87, valued at
$241k
Exercised 71,428 options to buy
@ $16.87, valued at
$1.2M
|
|
| 05/10/2023 |
4
| ROBERTSON SANFORD (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Exercised 3,571 options to buy
@ $19.6, valued at
$70k
Exercised 3,571 options to buy
@ $16.66, valued at
$59.5k
Exercised 2,142 options to buy
@ $16.66, valued at
$35.7k
|
|
| 05/08/2023 |
4
| SCANNON PATRICK J MD PHD (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 20,000 options to buy
@ $22.34, valued at
$446.8k
|
|
| 05/08/2023 |
4
| ROBERTSON SANFORD (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 20,000 options to buy
@ $22.34, valued at
$446.8k
Granted 5,000 options to buy
@ $22.34, valued at
$111.7k
|
|
| 05/08/2023 |
4
| O DONNELL MICHAEL J (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 20,000 options to buy
@ $22.34, valued at
$446.8k
|
|
| 05/08/2023 |
4
| GUSSIN ROBERT Z (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 20,000 options to buy
@ $22.34, valued at
$446.8k
Granted 5,000 options to buy
@ $22.34, valued at
$111.7k
|
|
| 05/08/2023 |
4
| Barry Richard (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Granted 20,000 options to buy
@ $22.34, valued at
$446.8k
Granted 5,000 options to buy
@ $22.34, valued at
$111.7k
|
|
| 05/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 05/01/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/01/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/16/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/16/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/08/2023 |
4
| O DONNELL MICHAEL J (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Paid exercise price by delivering 2,361 shares
@ $25.2, valued at
$59.5k
Paid exercise price by delivering 2,778 shares
@ $25.2, valued at
$70k
Exercised 3,571 options to buy
@ $19.6, valued at
$70k
Exercised 3,571 options to buy
@ $16.66, valued at
$59.5k
|
|
| 03/08/2023 |
4
| Barry Richard (Director) has filed a Form 4 on CASSAVA SCIENCES INC|
Txns:
| Bought 11,565 shares
@ $26.13, valued at
$302.2k
Bought 77,276 shares
@ $25.76, valued at
$2M
|
|
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
SC 13G/A
| CASSAVA SCIENCES INC reports a 4.7% stake in Cassava Sciences, Inc. |
| 02/07/2023 |
5
| BARBIER REMI (President and CEO) has filed a Form 5 on CASSAVA SCIENCES INC |
| 01/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/03/2023 |
5
| FRIEDMANN NADAV (Chief Medical Officer) has filed a Form 5 on CASSAVA SCIENCES INC |
|